体能良好的老年晚期MDS患者:谁最可能从移植中获益?
该前瞻性观察研究纳入两个中心290例60-75岁体能良好的晚期MDS患者,其中175例为不良风险、115例为标准风险伴严重血细胞减少。113例接受了HCT(中位5个月),中位随访39.5个月。多变量分析显示,不良风险患者接受HCT死亡风险显著降低(HR 0.57,p=0.01),而标准风险伴严重血细胞减少者未见获益(HR 1.33,p=0.36)。
要点
- 不良风险MDS老年患者接受HCT死亡风险显著降低(HR 0.57,p=0.01)。
- 标准风险伴严重血细胞减少者接受HCT未见生存获益(HR 1.33,p=0.36)。
- 入组后5个月内早期移植者死亡风险更低(HR 0.64,p=0.04)。
核心结论
- 在体能良好的老年晚期MDS患者中,不良风险疾病或早期接受HCT者生存显著改善,而标准风险伴严重血细胞减少者未见获益。
研究设计与样本
- 前瞻性观察研究,两个中心共纳入290例60-75岁体能良好的晚期MDS患者。
- 175例按不良MDS风险入组,115例按标准风险伴严重血细胞减少入组;113例接受HCT,中位5个月;全体中位随访39.5个月。
主要发现
- 单变量分析中,HCT对比非HCT的死亡HR为0.84(p=0.30)。
- 入组后≤5个月接受HCT者死亡HR为0.64(p=0.04),>5个月者为1.20(p=0.39)。
- 多变量分析控制年龄、性别、ECOG体能状态、细胞遗传学风险和IPSS风险组后,HCT对比非HCT的死亡HR为0.75(p=0.13)。
- 多变量分析中,不良MDS风险者HCT死亡HR为0.57(p=0.01),标准风险伴严重血细胞减少者为1.33(p=0.36)。
临床怎么用
- 对体能良好的60-75岁不良风险晚期MDS患者,可考虑尽早(入组后≤5个月)行HCT以改善生存。
- 标准风险伴严重血细胞减少的体能良好老年MDS患者,HCT未见生存获益,决策需谨慎权衡。
局限性
- 为前瞻性观察性研究而非随机对照,HCT与非HCT组间比较可能受混杂因素影响。
- 仅纳入两个中心、60-75岁体能良好患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a prospective observational study of fit adults aged 60-75 with advanced MDS, enrolled hierarchically for adverse MDS risk (intermediate-2 or high-risk international prognostic score [IPSS], low or intermediate-1 IPSS with poor-risk cytogenetics, or therapy-related MDS) or standard risk with severe cytopenia. A total of 290 patients enrolled at two centers: 175 for adverse risk and 115 for standard risk with severe cytopenia. 113 underwent HCT after a median of 5 months; median follow-up for all was 39.5 months. In univariable analyses, the hazard ratio (HR) for death comparing HCT with no HCT was 0.84 (p = 0.30). The HR for death was 0.64 (p = 0.04) for HCT ≤ 5 months after enrollment and 1.20 (p = 0.39) for HCT > 5 months. In multivariable analyses controlling for age, gender, ECOG performance status, cytogenetic risk, and IPSS risk group, HR for death was 0.75 (p = 0.13) for HCT compared to no HCT, 0.57 (p = 0.01) for adverse MDS risk and 1.33 (p = 0.36) for standard risk with severe cytopenia. In this large, prospective cohort of fit older adults with advanced MDS, we found that survival was significantly improved if HCT was performed early or for adverse risk disease but not for standard risk disease with severe cytopenia.
引用
- Abel GA, Kim HT, Hantel A, et al. Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2020. PMID: 33204012. doi:10.1038/s41375-020-01092-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。